Jun 23, 2022 / 03:00AM GMT
Unidentified Participant
(audio already in progress) finally coming to fruition. NeuroScientific Biopharmaceuticals is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative diseases such as Alzheimer's, multiple sclerosis, and also glaucoma, now the nasty conditions in all diseases with high unmet medical need.
So, they've got a lead drug. And I know those of you who are regulars at this conference will have heard of it before, EmtinB TM, well, which really for that initial Phase 1 trial, isn't it, in human beings. Which really, it's just about there. You've got a few approvals.
But look, let's welcome NeuroScientific CEO and Managing Director, Matt Liddelow, to tell us more. Would you please make him welcome, everyone?
Matt Liddelow - NeuroScientific Biopharmaceuticals Limited - Managing Director & CEO
Cheers, thanks very much, Chrissy. And it's great to be back here again and actually in a place I want to mingle with shareholders and potential new investors, I've got to say,
NeuroScientific Biopharmaceuticals Ltd at Vertical Events Gold Coast Investment Showcase Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot